Gh Research Plc Stock Price, News & Analysis

GH Research PLC (Nasdaq: GHRS) has reported its financial results for the year ending December 31, 2022, with a net loss of $22.5 million ($0.432 loss per share), up from a $9.2 million loss in 2021. The company's cash position decreased to $251.7 million from $276.8 million.

Significant business updates include the initiation of a Phase 2b trial for its inhalable mebufotenin product, GH001, targeting treatment-resistant depression. The company also expects to submit an IND for a new aerosol delivery device in Q3 2023 and has expanded its patent portfolio to 11 families.

GH Research PLC (Nasdaq: GHRS) announced significant advancements in its clinical trials and product development. The company received initial approvals for a Phase 2b trial of GH001 for treatment-resistant depression (TRD), set to begin in Q1 2023. A proprietary aerosol delivery device for GH001 is in progress, with an IND submission anticipated in Q3 2023. Additionally, a Phase 1 trial for GH002 has started, expected to conclude in Q4 2023. The company has filed a new patent application, expanding its portfolio to 11 families. Mebufotenin has been selected as the International Nonproprietary Name for 5-MeO-DMT.

GH Research PLC (Nasdaq: GHRS) reported Q3 2022 financial results, showing a net loss of $0.4 million ($0.008 loss per share), a reduction from a $1.8 million loss in Q3 2021. Cash reserves stand at $256.9 million, expected to fund operations into 2025. R&D expenses rose to $4.6 million, up from $2.6 million year-over-year, while G&A expenses decreased slightly to $2.0 million. The company is advancing clinical trials for its product candidate GH001 aimed at treatment-resistant depression, bipolar II disorder, and postpartum depression, with trials expected to commence in early 2023.

GH Research PLC (Nasdaq: GHRS) reported its Q2 2022 financial results, showing a net profit of $0.3 million ($0.006 per share), compared to a net loss of $2.1 million in Q2 2021. The company had $265.4 million in cash, sufficient to fund operations through 2025. R&D expenses rose to $4.2 million due to increased clinical activity, while G&A expenses surged to $2.5 million mainly due to higher insurance and employee costs. GH001 clinical trials for treatment-resistant depression have advanced, with regulatory applications planned for mid-Q3 2022. The company remains focused on 5-MeO-DMT therapies.

GH Research PLC (Nasdaq: GHRS) reported first quarter 2022 financial results, revealing a cash position of $270.8 million, projected to cover expenses until 2025. R&D expenses surged to $4.7 million, up from $692k, driven by increased clinical trial activities. General and administrative expenditures also rose to $3.3 million, compared to $448k in 2021. The net loss was $5.8 million, or $0.111 per share, compared to a loss of $1.1 million or $0.038 per share in Q1 2021. Positive developments include plans for clinical trials on GH001 targeting treatment-resistant depression, bipolar disorder, and postpartum depression.

GH Research PLC (Nasdaq: GHRS) announced its financial results for the year ended December 31, 2021. The company reported a cash position of $276.8 million, a significant increase from $5.9 million in 2020. R&D expenses surged to $8.6 million as clinical trials accelerated. The net loss expanded to $9.2 million or $0.211 loss per share, compared to $446 thousand loss in 2020. GH001, their inhalable 5-MeO-DMT product for treatment-resistant depression, showed promising Phase 2 trial results. The company plans further trials in 2022, aiming for a multi-center Phase 2b trial and additional indications.

GH Research PLC (Nasdaq: GHRS) reported its Q3 2021 financial results, highlighting a substantial cash position of $280.7 million as of September 30, improving from $5.9 million at the end of 2020. R&D expenses surged to $2.6 million due to intensified technical and clinical activities, contrasted with $55 thousand in Q3 2020. The net loss was $1.8 million, or $0.035 per share. Notably, the company announced positive results from the Phase 2 part of its clinical trial for GH001 in treatment-resistant depression, achieving 87.5% remission in patients at day 7.

GH Research PLC (Nasdaq: GHRS) announced successful results from the Phase 2 part of its clinical trial for GH001, an inhalable 5-MeO-DMT therapy targeting treatment-resistant depression (TRD). The primary endpoint was met, with 87.5% of patients achieving remission by day 7 (p<0.0001). Secondary endpoints were also met, showing a mean MADRS score change of -24.4 points (76%) at day 7 (p<0.0001). GH001 was well tolerated with no serious adverse events reported. Preliminary safety results from a Phase 1 trial confirmed the safety profile beyond day 7.

GH Research PLC (NASDAQ: GHRS) announced its business updates and financial results for Q2 2021, revealing significant developments in its clinical programs and corporate structure. The company raised $167.7 million through an IPO, issuing 11.5 million shares at $16.00 each. Cash reserves surged to $292.6 million. R&D expenses rose to $2 million due to ongoing clinical trials, while G&A expenses increased to $719,000 as a result of IPO preparations. The net loss for the quarter was $2.1 million, translating to a loss per share of $0.053.